Cargando…

Wearing-off Identification in Parkinson's Disease: The shapd-woq Study

Objectives: To clarify the frequency of wearing-off phenomenon (WO) and the validity of the Chinese version of the 9-item wearing-off questionnaire (CWOQ-9) in WO identification in this large population. Methods: Parkinson's patients treated with antiparkinsonian medications were consecutively...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Ying, Yuan, Canxing, Hou, Xiaojun, Chen, Wei, Wang, ChunYan, Gao, Shan, Wang, Yuhui, Jin, Lingjing, Liu, Zhenguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083219/
https://www.ncbi.nlm.nih.gov/pubmed/32231634
http://dx.doi.org/10.3389/fneur.2020.00116
_version_ 1783508491662524416
author Wan, Ying
Yuan, Canxing
Hou, Xiaojun
Chen, Wei
Wang, ChunYan
Gao, Shan
Wang, Yuhui
Jin, Lingjing
Liu, Zhenguo
author_facet Wan, Ying
Yuan, Canxing
Hou, Xiaojun
Chen, Wei
Wang, ChunYan
Gao, Shan
Wang, Yuhui
Jin, Lingjing
Liu, Zhenguo
author_sort Wan, Ying
collection PubMed
description Objectives: To clarify the frequency of wearing-off phenomenon (WO) and the validity of the Chinese version of the 9-item wearing-off questionnaire (CWOQ-9) in WO identification in this large population. Methods: Parkinson's patients treated with antiparkinsonian medications were consecutively recruited into this observational, cross-sectional investigation. Patients completed the CWOQ-9 prior to the independent clinician assessment. Results: A total of 1,385 patients were included in the analysis. The mean age was 69.7 ± 9.5 years and the mean disease duration was 5.8 ± 4.7 years. Clinicians identified WO in 763 patients, with an overall prevalence of 55.1%. In patients within 1 year of disease duration, clinicians diagnosed WO in eight patients, with a percentage of 12.9%. With the disease progression, the WO frequency gradually increased to 76.2% in patients with 10–15 years of disease duration. Then, it slowly decreased at a longer disease duration. The occurrence of WO was closely associated with the disease duration, H&Y staging, and levodopa daily dose. CWOQ-9 identified 1,071 patients (1071/1398, 77.33%) that had WO-related symptoms. The mean CWOQ-9 score was 3.4 ± 1.6. CWOQ-9 corresponded with clinician assessments of WO in 734 of 763 cases; clinicians disagreed with the CWOQ-9 considering the presence of WO in 337 of 1,071 cases. The sensitivity and specificity of CWOQ-9 were 96.2 and 45.8%, respectively. Conclusions: WO occurred frequently at the early and middle stage of PD. CWOQ-9 was qualified as a pre-visiting screening tool for clinicians to better identify WO.
format Online
Article
Text
id pubmed-7083219
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70832192020-03-30 Wearing-off Identification in Parkinson's Disease: The shapd-woq Study Wan, Ying Yuan, Canxing Hou, Xiaojun Chen, Wei Wang, ChunYan Gao, Shan Wang, Yuhui Jin, Lingjing Liu, Zhenguo Front Neurol Neurology Objectives: To clarify the frequency of wearing-off phenomenon (WO) and the validity of the Chinese version of the 9-item wearing-off questionnaire (CWOQ-9) in WO identification in this large population. Methods: Parkinson's patients treated with antiparkinsonian medications were consecutively recruited into this observational, cross-sectional investigation. Patients completed the CWOQ-9 prior to the independent clinician assessment. Results: A total of 1,385 patients were included in the analysis. The mean age was 69.7 ± 9.5 years and the mean disease duration was 5.8 ± 4.7 years. Clinicians identified WO in 763 patients, with an overall prevalence of 55.1%. In patients within 1 year of disease duration, clinicians diagnosed WO in eight patients, with a percentage of 12.9%. With the disease progression, the WO frequency gradually increased to 76.2% in patients with 10–15 years of disease duration. Then, it slowly decreased at a longer disease duration. The occurrence of WO was closely associated with the disease duration, H&Y staging, and levodopa daily dose. CWOQ-9 identified 1,071 patients (1071/1398, 77.33%) that had WO-related symptoms. The mean CWOQ-9 score was 3.4 ± 1.6. CWOQ-9 corresponded with clinician assessments of WO in 734 of 763 cases; clinicians disagreed with the CWOQ-9 considering the presence of WO in 337 of 1,071 cases. The sensitivity and specificity of CWOQ-9 were 96.2 and 45.8%, respectively. Conclusions: WO occurred frequently at the early and middle stage of PD. CWOQ-9 was qualified as a pre-visiting screening tool for clinicians to better identify WO. Frontiers Media S.A. 2020-03-13 /pmc/articles/PMC7083219/ /pubmed/32231634 http://dx.doi.org/10.3389/fneur.2020.00116 Text en Copyright © 2020 Wan, Yuan, Hou, Chen, Wang, Gao, Wang, Jin and Liu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Wan, Ying
Yuan, Canxing
Hou, Xiaojun
Chen, Wei
Wang, ChunYan
Gao, Shan
Wang, Yuhui
Jin, Lingjing
Liu, Zhenguo
Wearing-off Identification in Parkinson's Disease: The shapd-woq Study
title Wearing-off Identification in Parkinson's Disease: The shapd-woq Study
title_full Wearing-off Identification in Parkinson's Disease: The shapd-woq Study
title_fullStr Wearing-off Identification in Parkinson's Disease: The shapd-woq Study
title_full_unstemmed Wearing-off Identification in Parkinson's Disease: The shapd-woq Study
title_short Wearing-off Identification in Parkinson's Disease: The shapd-woq Study
title_sort wearing-off identification in parkinson's disease: the shapd-woq study
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083219/
https://www.ncbi.nlm.nih.gov/pubmed/32231634
http://dx.doi.org/10.3389/fneur.2020.00116
work_keys_str_mv AT wanying wearingoffidentificationinparkinsonsdiseasetheshapdwoqstudy
AT yuancanxing wearingoffidentificationinparkinsonsdiseasetheshapdwoqstudy
AT houxiaojun wearingoffidentificationinparkinsonsdiseasetheshapdwoqstudy
AT chenwei wearingoffidentificationinparkinsonsdiseasetheshapdwoqstudy
AT wangchunyan wearingoffidentificationinparkinsonsdiseasetheshapdwoqstudy
AT gaoshan wearingoffidentificationinparkinsonsdiseasetheshapdwoqstudy
AT wangyuhui wearingoffidentificationinparkinsonsdiseasetheshapdwoqstudy
AT jinlingjing wearingoffidentificationinparkinsonsdiseasetheshapdwoqstudy
AT liuzhenguo wearingoffidentificationinparkinsonsdiseasetheshapdwoqstudy